Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGIZEKids-T
NCT07506863Phase 3Recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in thalassemia comparing Mitapivat with Placebo (2 arms). Primary endpoint: Transfusion Reduction Response at Week 48. Started Sep 2026; status: recruiting.
02
Drugs
mitapivat
03
Conditions
thalassemia
Beyond the preview
Go deeper on NCT07506863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07506863.